Follicular lymphoma (FL) is the most common indolent lymphoma in the United States with
an incidence of 3.4 patients per 100,000 and an estimated 13,960 new patients diagnosed …

Standard of care for patients with symptomatic, advanced‐stage follicular lymphoma (FL) is
rituximab‐containing chemoimmunotherapy followed by rituximab maintenance. This …

7076 Background: Odronextamab, an off-the-shelf CD20× CD3 bispecific antibody, has
shown compelling efficacy (objective response rate [ORR] 80%, complete response [CR] …

Population-based data comparing the outcomes of patients with transformed follicular
lymphoma (t-FL) and de novo diffuse large B-cell lymphoma (DLBCL) are lacking. The …

The treatment of follicular lymphoma (FL) continues to evolve. Those patients who present
with minimal symptoms often are observed without therapy until significant progression …

The NLCS is a multi-center, disease-based, longitudinal, observational study designed to
collect information on treatment regimens and outcomes for patients (pts) with newly …

FL, the most prevalent indolent lymphoma in the US, is less common in non-White
populations including African Americans (AA) and Hispanics (H), limiting our knowledge …

Purpose The randomised, controlled OSHO# 39 study showed promising results using first-
line mitoxantrone, chlorambucil and prednisolone (MCP) chemotherapy plus rituximab in …

Introduction: National guidelines recommend observation without active therapy (" watchful
waiting", WW) for follicular lymphoma (FL) presenting in advanced stage with low burden of …

Introduction While radiotherapy is the established standard of care for limited stage, grade 1-
2 follicular lymphoma (FL), the management of localized grade 3A (FL3A) disease remains …